Company intelligence / Profile preview
Shanghai First Song Therapeutics
Shanghai, Shanghai Shi, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Shanghai First Song Therapeutics is an innovative Chinese biotechnology company focused on developing, manufacturing, and commercializing autologous and dual-targeting chimeric antigen receptor T-cell (CAR-T) immunotherapies. The company has several active clinical-stage programs targeting both solid tumors and hematological malignancies. Its lead assets are in Phase I trials for indications such as gastric, colorectal, breast, pancreatic, esophageal cancers and lymphoma. Early results from ongoing studies are not yet published in detail.
- Therapeutic areas
- OncologyRheumatologyImmunology
- Modalities
- Autologous CAR-T cell therapiesGene therapiesImmunotherapies
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Shanghai First Song Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai First Song Therapeutics.